
Bio-Techne Corporation (TECH)
77.40 USD +2.89 (+3.88%) Volume: 0.77M
Bio-Techne Corporation’s stock price has experienced a positive surge, trading at 77.40 USD with an impressive uptick of +3.88% this session. The biotechnology giant has seen a trading volume of 0.77M, maintaining a steady Year-to-Date (YTD) percentage change of +0.31%, highlighting its resilient market performance.
Latest developments on Bio-Techne Corporation
Today, Bio-Techne Corp (NASDAQ: TECH) stock price experienced movements following key events in the market. State Street Corp disclosed a substantial $511.23 million stock holding in Bio-Techne Co., indicating confidence in the company’s performance. Additionally, Worldquant Millennium Advisors LLC purchased 22,185 shares and Tenere Capital LLC bought 45,992 shares of Bio-Techne Co., further influencing the stock price. These transactions reflect positive sentiments towards Bio-Techne Corp and may have contributed to today’s stock price fluctuations.
Bio-Techne Corporation on Smartkarma
Analysts at Baptista Research have been closely monitoring Bio Techne Corp, a leading life sciences company. In their recent research reports, they highlighted the company’s solid performance in the first quarter of Fiscal Year 2025, with a 4% year-over-year organic revenue growth. This growth was attributed to the stabilization of biopharma end markets and robust execution in areas like cell and gene therapy. Baptista Research aims to evaluate various factors that could impact the company’s stock price in the near future and has conducted an independent valuation using a Discounted Cash Flow (DCF) methodology.
In another report by Baptista Research, they focused on Bio Techne Corp‘s enhanced investment in molecular diagnostics. Despite a challenging external environment with reduced biotech funding and budget recalibrations from large pharmaceutical entities and academia, the company announced modest organic revenue growth of 1% year-over-year in the fourth quarter of fiscal year 2024. Baptista Research continues to analyze factors influencing the company’s stock price and is committed to providing valuable insights for investors on Smartkarma.
A look at Bio-Techne Corporation Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Bio Techne Corp has a promising long-term outlook. With a strong momentum score of 4, the company is showing positive performance trends that could lead to future growth. Additionally, Bio Techne Corp scores well in the value and growth categories, indicating that it offers good value for investors and has potential for expansion.
However, the company’s lower scores in the dividend and resilience categories suggest that there may be some challenges ahead in terms of financial stability and consistent payouts to shareholders. Overall, Bio Techne Corp‘s focus on developing, manufacturing, and selling biotechnology products positions it well in the market, and with continued momentum, the company could see further success in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars